JPMorgan analyst Anupam Rama lowered the firm’s price target on Sarepta to $213 from $217 and keeps an Overweight rating on the shares. The analyst updated the company’s model post the approval of Elevidys in 4-5 year-old Duchenne muscular dystrophy patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRPT: